Keen On NASDAQ Slot, Concentra Looks To Scupper Jounce And Redx Merger
Mystery Firm Makes Last Minute Bid
In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.
